These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 36551586)
21. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251 [TBL] [Abstract][Full Text] [Related]
22. Case report: Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L Front Oncol; 2022; 12():1095779. PubMed ID: 36620595 [TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Han Y; Wang J; Wang Z; Xu B Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis. Dai Q; Wang Y; Liao M; Chen H Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998 [TBL] [Abstract][Full Text] [Related]
25. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188 [TBL] [Abstract][Full Text] [Related]
26. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454 [TBL] [Abstract][Full Text] [Related]
27. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934 [TBL] [Abstract][Full Text] [Related]
28. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300 [TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934 [TBL] [Abstract][Full Text] [Related]
31. Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis. Liu YS; Dong K; Park C Rev Cardiovasc Med; 2023 Nov; 24(11):309. PubMed ID: 39076428 [TBL] [Abstract][Full Text] [Related]
32. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267 [TBL] [Abstract][Full Text] [Related]
33. Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. Wang Y; Xu H; Han Y; Wu Y; Sa Q; Wang J ESMO Open; 2023 Jun; 8(3):101216. PubMed ID: 37084609 [TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis. Tong F; Lu Y; Ma HF; Shen J Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268 [TBL] [Abstract][Full Text] [Related]
35. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Alvarez A; Bernal AM; Anampa J Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909 [TBL] [Abstract][Full Text] [Related]
36. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data. Martin JM; Handorf EA; Montero AJ; Goldstein LJ Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450 [TBL] [Abstract][Full Text] [Related]
37. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172 [TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis. Dong L; Zhu LN; Xie BJ; Li JB; Ding T; Jiang YF; Zhu ZN Pharmacotherapy; 2019 Dec; 39(12):1126-1136. PubMed ID: 31692005 [TBL] [Abstract][Full Text] [Related]
39. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012 [TBL] [Abstract][Full Text] [Related]
40. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]